[Antitumor action of RNAses modified by covalent binding with dextran m-aminobenzylhydroxymethyl ether].
Antitumor effect of pancreatic RNase and RNase from Actinomyces rimosus, as well as of their derivatives modified by dextran m-aminobenzylhydroxymethyl ether under different conditions was studied and compared. It was found that the efficacy of actinomycetous enzyme and its modified derivatives was superior to that of the analogous preparations of pancreatic RNase. Antitumor effect of the modified enzymes was higher than that of the native ones and depended on the modification conditions. It is concluded that biological efficacy of the RNases is determined by their origin and physico-chemical properties.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D003911:Dextrans / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004720:Endonucleases / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D004987:Ethers / Q000627:therapeutic use; D008297:Male; D051379:Mice; D010179:Pancreas / Q000201:enzymology; D011485:Protein Binding / Q000187:drug effects; D006163:Ribonuclease T1 / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D012259:Ribonuclease, Pancreatic; D012260:Ribonucleases / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D012511:Sarcoma 37 / Q000188:drug therapy; D013302:Streptomyces / Q000201:enzymology
D000970:Antineoplastic Agents; D003911:Dextrans; D004987:Ethers; D004720:Endonucleases; D012260:Ribonucleases; D006163:Ribonuclease T1; D012259:Ribonuclease, Pancreatic
Protivoopukholevoe deĭstvie RNK-az, modifitsirovannykh kovalentnym sviazyvaniem s m-aminobenziloksimetilovym éfirom dekstrana.